Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations

Journal of Thrombosis and Thrombolysis

Volumn 41, Issue 3, 2016, Pages 475-481

  Vandiver, Jeremy W ^a,b   Ritz, Leticia I ^b,c   Lalama, Jeffrey T ^b,c  

^a UNIVERSITY OF WYOMING SCHOOL OF PHARMACY   (United States)

^b SWEDISH MEDICAL CENTER   (United States)

^c REGIS UNIVERSITY   (United States)

Author keywords

DVT; Enoxaparin; Heparin; LMWH; Obesity; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; POLYSACCHARIDE;

BLOOD LEVEL; BODY MASS; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MORBID OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; BLEEDING; BLOOD; CHEMICALLY INDUCED; COMPLICATION; FEMALE; MALE; METABOLISM; OBESITY, MORBID; VENOUS THROMBOSIS;

FACTOR XA; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; OBESITY, MORBID; POLYSACCHARIDES; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84929698619     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-015-1231-5     Document Type: Review

References (37)

1. Cushman M (2007) Epidemiology and risk factors for venous thrombosis. Semin Hematol 44(2):62–69
2. Kitahara CM, Flint AJ, Berrington de Gonzalez A et al (2014) Association between class III obesity (BMI of 40–59 kg/m2) and mortality: a pooled analysis of 20 prospective studies. PLoS Med 11(7):e1001673
3. Allman-Farinelli MA (2011) Obesity and venous thrombosis: a review. Semin Thromb Hemost 37(8):903–907
4. Frederiksen SG, Hedenbro JL, Norgren L (2003) Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg 90:547–548
5. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE (2009) Low-molecular weight heparins in renail impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 43:1064–1083
6. Vitoux JF, Aiach M, Roncato M, Fiessinger JN (1988) Should thrombophrophylactic dosage of low molecular weight heparin be adapted to patient’s weight? Thromb Haemost 59(1):120
7. Mayr AJ, Dunsxer M, Jochberger S et al (2002) Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res 105:201–204
8. Jimenez D, Diaz G, Iglesias A et al (2008) Anti-factor Xa activity of enoxaparin for thromboprophylaxis in nonsurgical patients is dependent on body mass. Arch Bronconeumol 44(12):660–663
9. Tripodi A, den Besselaar A (2009) Laboratory monitoring of anticoagulation: where do we stand? Semin Thromb Hemost 35:34–41
10. Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:188S–203S
11. Garcia DA, Baglin TP, Weitz J, Samama MM (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e24S–e43S
12. Levine MN, Planes A, Hirsh J et al (1989) The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 62(3):940–944
13. Turpie AGG (1989) The relationship between ex vivo anti-factor Xa levels and efficacy/safety of low molecular weight heparin. Br J Clin Pract Suppl 65:18–23
14. Malinoski D, Jafari F, Ewing T et al (2010) Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma 68(4):874–880
15. Samama MM (1995) Contemporary laboratory monitoring of low molecular weight heparins. Clin Lab Med 15(1):119–123
16. Bates SM, Greer IA, Middledorp S et al (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic Therapy and Prevention of Thrombosis 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2):e691S–e736S
17. Walenga JM (1991) Laboratory monitoring of the clinical effects of low molecular weight heparins. Thromb Res Suppl 14:49–62
18. Holmer E, Mattsson C, Nilsson S (1982) Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 25(6):475–485
19. Desjardins L, Bara L, Boutitie F et al (2004) Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study. Arch Pathol Lab Med 128:519–526
20. Bara L, Planes A, Samama MM (1999) Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and d-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin, or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 104:230–240
21. Bara L, Leizorovicz A, Picolet H, Samama M (1992) Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either logiparin (LMWH) or unfractionated heparin. Thromb Res 65:641–650
22. Leyvraz PF, Bachmann F, Hoek J et al (1991) Prevention of deep vein thrombosis after hip replacement: randomized comparison between unfractionated heparin and low molecular weight heparin. BMJ 303:543–548
23. Kovacs MJ, Weir K, MacKinnon K et al (1998) Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery. Thromb Res 91:137–142
24. Rowan BO, Kuhl DA, Lee MD, Tichansky DS, Madan AK (2008) Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg 18:162–166
25. Freeman A, Horner T, Pendleton RC, Rondina MT (2012) Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Am J Hematol 87(7):740–743
26. Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC (2010) Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese medically-ill patients. Thromb Res 125:220–223
27. Bickford A, Majerick S, Bledsoe J et al (2013) Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient. Am J Surg 206:847–852
28. Ludwig KP, Simons HJ, Mone M, Barton RG, Kimball EJ (2011) Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. Ann Pharmacother 45:1356–1362
29. Scholten DJ, Hoedema RM, Scholten SE (2002) A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 12:19–24
30. Borkgren-Okonek MJ, Hart RW, Pantano JE et al (2008) Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis 4(5):625–631
31. Barbar S, Noventa F, Rossetto V et al (2010) A risk assessment model for the identifi cation of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 8(11):2450–2457
32. Kahn SR, Lim W, Dunn AS et al (2012) Prevention of VTE in nonsurgical patients: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). Chest 141(2 Suppl):e195S–e226S
33. Wang T, Milligan PE, Wong CE et al (2014) Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thromb Haemost 111:88–93
34. Geerts WH, Berqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:381S–453S
35. Gould MK, Garcia DA, Wren SM et al (2012) Prevention of VTE in nonorthopedic surgical patients. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). Chest 141(2 Suppl):e227S–e277S
36. Clinical Issues Committee of the American Society for Metabolic and Bariatric Surgery (2007) Prophylactic measures to reduce the risk of venous thromboembolism in bariatric surgery patients. Surg Obes Relt Dis 3(5):494–495
37. Martinez L, Burnett A, Borrego M et al (2011) Effect of fondaparinux prophylaxis on anti-factor Xa concentrations in patients with morbid obesity. Am J Health Syst Pharm 68:1716–1722